Evidence types
Phase 1 clinical trial articles covering early human safety, dosing, and first-in-human treatment research relevant to IBD.
Page 2 of 3 · 124 articles
Patients and clinicians often seek adjunctive options to improve symptoms, quality of life, or reduce treatment burden. This trial tests whether Bacillus spore probiotics added to standard care can provide measurable...
Mapping microbes and metabolites directly from different gut regions could reveal location-specific changes linked to IBD activity and help researchers develop better biomarkers or targeted treatments.
Faster, reliable reading of capsule endoscopy videos could shorten diagnostic delays and make small-bowel evaluation easier for people with suspected Crohn’s disease. If AI preserves accuracy while reducing review time,...
IBD patients sometimes have low iron or zinc and may try supplements. This trial tested whether two phytase-containing dietary supplements are acceptable and whether they change iron and zinc absorption in adults with...
A new oral drug, LMT503, is entering first-in-human testing for people with Crohn's disease and ulcerative colitis. Early-phase trials establish safety and how the body handles a drug—important first steps before any...
Mental health symptoms are common in people with IBD and may be influenced by both psychological and biological factors. A virtual, group psychotherapy program tailored to IBD could increase access to treatment and help...
The study explores breath VOCs as a possible noninvasive biomarker for IBD activity, which could offer easier, more acceptable monitoring than colonoscopy or stool tests.
This registry will track long-term safety and clinical outcomes in children with IBD, with a focus on infliximab (an anti‑TNF biologic) versus non‑biologic therapies. Long follow-up could help identify uncommon or late...
This trial tests a new oral live biotherapeutic designed to affect inflammation and the gut microbiome in Crohn’s disease. Early‑phase safety and pharmacodynamic results could influence future development of...
Sleep problems are common in Crohn’s disease and may worsen symptoms, pain, and inflammation. This trial is testing whether a remotely delivered insomnia treatment is feasible and whether improving sleep could also...
Chronic pain is common in people with Crohn’s disease and ulcerative colitis and can persist despite controlling gut inflammation. Brief online pain-education programs could offer a low-burden, scalable way to reduce...
This trial could show whether intra-operative ultrasound can be used reliably to choose the proximal resection margin during ileocecal resection for terminal ileal Crohn’s disease—information that might affect surgical...
Non-invasive, inexpensive blood-derived ratios could offer easier, more frequent assessment of IBD activity than repeat endoscopy. This study evaluates several such ratios (CAR, PAR, NLR, FAR, Hb/CRP) against clinical...
Perianal fistulizing Crohn’s disease is difficult to treat and many patients don’t respond to available medical and surgical options. This trial tests an existing wound‑healing therapy (HBOT) in a formal controlled...
This trial tests whether a seaweed-derived fucoidan given with standard 5-ASA therapy can change biomarkers linked to mucosal healing (fecal calprotectin, fecal short-chain fatty acids) and stool consistency in people...
Researchers and patients tracking new IBD therapies may care because this is the first human study of a GlaxoSmithKline investigational drug aimed at colitis/ulcerative colitis — an early step that could lead to future...
This study will collect real-world data on etrasimod, an oral S1P receptor modulator, in people with ulcerative colitis, using patient-reported symptom measures over one year — information that may help patients and...
Researchers are testing whether baseline fecal microbiome profiles can predict who with mild ulcerative colitis will benefit from a specific prebiotic supplement. If validated, this approach could move dietary therapy...
This trial tests whether the common sweetener sucralose alters the gut microbiome in people with Crohn’s disease in remission compared with healthy volunteers.
Early-phase trials test whether new treatments are safe and show biological activity. This study measures fecal calprotectin, a biomarker of intestinal inflammation, so it could provide early signals about whether ND-12...
This trial tests a mushroom-derived dietary supplement in people with mild-to-moderate UC or colonic/ileal Crohn's disease, measuring symptoms, fecal biomarkers, and endoscopic activity—outcomes that matter to patients...
Ustekinumab treats Crohn’s disease and ulcerative colitis; a biosimilar that shows similar pharmacokinetics and safety could expand treatment options and affect availability and cost.
Based on the title and source metadata, this appears to be a clinical trial phase 1 related to Research and clinical trials. The original article is from firstwordpharma.com.
People with an ileal pouch after UC/IBDU often struggle with fecal incontinence and reduced quality of life. This trial is testing a noninvasive device (Emsella chair) aimed at improving incontinence and patient-reported...
A new oral investigational drug (HRS-7085) is entering early human testing for moderate-to-severe ulcerative colitis. People with UC who have not benefited from approved therapies may be interested in trial options and...
Pouchitis is a common complication after IPAA and noninvasive tools to detect inflammation could make monitoring easier and less burdensome than repeated pouchoscopy. This trial tested whether intestinal ultrasound can...
A large clinical registry can help researchers learn more about IBD patterns, potential causes, and who might be eligible for future clinical trials. For patients, joining may help advance research and make it easier to...
This news matters because SL-325 targets the TL1A/DR3 pathway, a novel immune target being tested for Crohn’s disease and UC; early Phase 1 data suggest a tolerable profile and prolonged target blockade that could affect...
Perianal fistulas are a serious complication of Crohn’s disease and can be hard to treat. This trial tested a novel extracellular-vesicle therapy (ExoFlo) delivered locally as a potential new option, so patients with...
This pilot trial explores a non-drug neuromodulation approach (auricular vagus nerve stimulation) that might influence brain–gut interactions, stress, fatigue, and quality of life in people with IBD in remission....
Early clinical data suggest SL-325 engages its target (TL1A) with a favorable safety signal, and a Phase 2b trial in Crohn’s disease is planned — meaning this could become a new treatment option in the future if later...
People with UC in remission who still have gut–brain interaction symptoms often look for safe ways to improve symptoms or gut microbiota balance.
Dietary strategies like the Mediterranean diet and time-restricted feeding could be low-risk ways to influence gut microbiota, short-chain fatty acids, and inflammation in people with ulcerative colitis; this trial will...
Patients on anti-TNF biologics often seek safe ways to support gut microbial health. This trial tests a prebiotic supplement (2'-FL) for safety and whether it increases beneficial bacteria and butyrate in young people...
Phase 1 platform studies like this one test safety and tolerability of new treatments for moderate-to-severe ulcerative colitis before larger trials. Findings from such early studies determine whether a drug moves...
People with moderate-to-severe Crohn's disease or ulcerative colitis and their clinicians may want to know how long patients stay on guselkumab in real-world care, since persistence reflects tolerability, benefit, and...
Early-phase trials test safety and tolerability of new mechanisms; this study evaluates an anti–IL-18 antibody (aletekitug) which could represent a different therapeutic approach for people with moderate-to-severe UC if...
People with moderate-to-severe Crohn’s disease may be interested because the study explores a new, repurposed drug (vorinostat) that targets epigenetic and immune pathways and includes a plan to move responding...
This trial tests a new oral drug (Alpha-0261) for moderate-to-severe ulcerative colitis and could matter to people who haven’t responded to standard medicines. Early-phase studies mainly assess safety but also collect...
EEN is being evaluated as a non‑pharmacologic induction therapy in adults with active and complicated Crohn’s disease; results could inform whether EEN helps induce remission, improve nutrition, and impact inflammation...
The study explores engineering HSPCs to induce IL-10–mediated, antigen-specific regulatory responses, which could lead to new cell-based strategies for children with refractory IBD who do not respond to current...
People with IBD sometimes are excluded from or uncertain about immune checkpoint inhibitor cancer trials because of concerns about triggering autoimmune flares. This trial explicitly studies safety and disease impact in...
MR enterography is an important tool to measure transmural inflammation in ileal Crohn's disease, but many patients find the oral distension agents unpleasant. Demonstrating that non-distended MR enterography yields...
A new bispecific antibody program (TL1A x IL-23p19) advancing toward patient trials could expand treatment options for people with ulcerative colitis and Crohn’s disease if later-stage trials confirm safety and efficacy....
The trial explores a new way to boost regulatory T cells using low-dose IL-2, which could offer an alternative mechanism for people with Crohn's disease who haven't responded to existing therapies. It also links immune...
The record concerns a planned surgical approach using a patient's own bone marrow–derived stem cells to try to heal fistulating perianal Crohn's disease—an often hard-to-treat complication that substantially affects...
Researchers are trying to create modular mucosal immunotherapies that target both microbial and inflammatory drivers of diseases like colitis. If successful, this approach could lead to treatments that address the...
This paper describes a new engineered, off-the-shelf regulatory T cell therapy (TRX103) designed to restore immune tolerance and that is already entering early clinical trials for treatment-refractory Crohn’s disease.
